Drug intelligence / Profile preview

PE002

Development stage: Preclinical
Lead developer: Letolab
Modality: Peptides

Overview

PE002 is a peptide-based biosimilar developed by Letolab that targets the glucagon-like peptide-1 (GLP-1) receptor. Currently in the lead optimization stage, it is being developed for the treatment of diabetes and weight loss (obesity). As a GLP-1 receptor agonist, PE002 mimics the physiological effects of the incretin hormone GLP-1, which includes stimulating insulin secretion in a glucose-dependent manner, inhibiting glucagon secretion, and slowing gastric emptying. These actions contribute to improved glycemic control and significant weight reduction, making it a candidate for metabolic disorders.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on PE002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PE002.

Explore the full profile